Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Clinical Dose-Ranging Trial to Evaluate Efficacy and Safety of a NMDA Antagonist for Oral Administration in Patients With Subjective Tinnitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jun 2015
Price :
$35
*
At a glance
- Drugs Neramexane (Primary)
- Indications Tinnitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merz Pharmaceuticals GmbH
- 10 Jun 2014 New trial record
- 28 Jan 2008
- 07 Dec 2006